1-7 of 7
Brian B. Tuch
Close
Sort by
Journal Articles

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Eric Lowe, BS, Andrea R Fan, PhD, Jing Jiang, Henry W. B. Johnson, PhD, Christopher J. Kirk, PhD, Dustin McMinn, PhD, Tony Muchamuel, MS, Yu Qian, PhD, Brian B. Tuch, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 408.
https://doi.org/10.1182/blood-2019-123782
Published: 2019
Journal Articles

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition

Kathryn G. Roberts, Laura J. Janke, Yaqi Zhao, Aman Seth, Jing Ma, David Finkelstein, Steve Smith, Kevin Ebata, Brian B. Tuch, Stephen P. Hunger, Charles G. Mullighan
Journal: Blood
Blood (2018) 132 (8): 861–865.
https://doi.org/10.1182/blood-2018-05-849554
Published: 2018
Includes: Supplemental data
Journal Articles

Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies

Justin Taylor, MD, Christina Marcelus, Dean Pavlick, Ryma Benayed, MD, Akihide Yoshimi, MD, Emiliano Cocco, PhD, Benjamin H Durham, MD BS, Jaclyn F Hechtman, MD, Young Rock Chung, MS, Kerry Mullaney, Justin M Watts, MD, Eli L Diamond, MD, Lee A Albacker, PhD, Tariq I Mughal, MD FRCP, Kevin Ebata, PhD, Brian B. Tuch, PhD, Nora Ku, MD, Maurizio Scaltriti, PhD, Maria E. Arcila, Siraj M Ali, MD PhD, David M. Hyman, MD, Omar Abdel-Wahab, MD, Jae H. Park, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 794.
https://doi.org/10.1182/blood.V130.Suppl_1.794.794
Published: 2017
Journal Articles

Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia

Kathryn G. Roberts, PhD, Olga Bridges, Laura J. Janke, PhD, Kevin Ebata, PhD, Brian B Tuch, PhD, Nisha Nanda, PhD, Charles Mullighan, MBBS, MSc, MD
Journal: Blood
Blood (2016) 128 (22): 278.
https://doi.org/10.1182/blood.V128.22.278.278
Published: 2016
Journal Articles

Immunoglobulin Expression Is a Major Determinant Of Patient Sensitivity To Proteasome Inhibitors

Brian B Tuch, Ph.D., Andrea Loehr, Ph.D., Jeremiah D Degenhardt, Ph.D., Kevin A Kwei, PhD, Jonathan J Keats, PhD, Christopher J. Kirk, Ph.D
Journal: Blood
Blood (2013) 122 (21): 1903.
https://doi.org/10.1182/blood.V122.21.1903.1903
Published: 2013
Journal Articles

A Method To Identify Copy Number Aberrations (CNAs) From Whole Exome Sequence (WES) Data and Its Application To Multiple Myeloma Cell Lines and Patient Samples

Jeremiah D Degenhardt, Ph.D., Kenneth B Hoehn, Kevin A Kwei, Ph.D., Jonathan J Keats, PhD, Christopher J. Kirk, PhD, Brian B Tuch, Ph.D.
Journal: Blood
Blood (2013) 122 (21): 4881.
https://doi.org/10.1182/blood.V122.21.4881.4881
Published: 2013
Journal Articles

Development Of Methods To Perform Next Generation Sequencing (NGS)-Based Genomics Studies On Multiple Myeloma Clinical Samples

Jonathan J Keats, PhD, Kevin A Kwei, PhD, Jeremiah D Degenhardt, Ph.D., Kristi Allen, BS, Christopher J. Kirk, Ph.D, Brian B Tuch, Ph.D.
Journal: Blood
Blood (2013) 122 (21): 5347.
https://doi.org/10.1182/blood.V122.21.5347.5347
Published: 2013